• Other
  • Exited

Cerecor Inc. is a clinical stage biopharmaceutical company developing innovative treatments for patients suffering from nervous system disorders.  Its lead program, CERC-301, is a first-in-class, oral, selective NR2B inhibitor in Phase 2 development as a once-a-day adjunctive therapy for severe MDD (major depressive disorder) with a rapid onset of action.  CERC-301 builds upon intravenous ketamine’s extensive clinical experience with a more selective and specific oral agent that has the potential for improved safety.